{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:58:26Z","timestamp":1784177906964,"version":"3.55.0"},"reference-count":70,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["831458"],"award-info":[{"award-number":["831458"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine what drives participation in clinical trials with decentralised elements and to estimate trial participation probabilities for trials with different degrees of decentralisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Patient preference study using a discrete choice experiment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Recruitment in primary, secondary, tertiary care and other settings in the Netherlands (NL), Austria (AT) and Germany (DE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>People with type 2 diabetes mellitus (T2DM) aged \u226518 years. A total of 787 people (NL n=276, AT n=265, DE n=246) participated in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Preferences for participation in clinical trials with different options for location and type of contact with the study team, activities to perform by participant, use of digital technologies by participant, number of scheduled contacts, trial duration, known safety and efficacy of the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>How much was known about the safety and efficacy of the drug was the most important element in the decision whether to participate in a clinical trial in all countries. The trial duration, location and type of contact with the study team, and number of scheduled contacts were other important elements. Participation probabilities for hypothetical trial scenarios differed between countries, with the highest rates for a decentralised trial involving video contact (NL: 89%; AT: 99%; DE: 84%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>People with T2DM prefer to take part in clinical trials with decentralised approaches. Information on preferences can help trialists and protocol developers to design and plan future trials that integrate patients\u2019 needs and thus reduce barriers to participation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107737","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:57:29Z","timestamp":1762325849000},"page":"e107737","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Do people prefer to take part in a clinical trial from home or come to site? A discrete choice experiment in type 2 diabetes mellitus"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-0807","authenticated-orcid":false,"given":"Julia","family":"Kopanz","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Lagerwaard","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorien","family":"Veldwijk","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands"},{"name":"Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-4233","authenticated-orcid":false,"given":"Julia K","family":"Mader","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Tews","sequence":"additional","affiliation":[{"name":"MVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas T","family":"van Sloten","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine and Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-8243","authenticated-orcid":false,"given":"Mira G P","family":"Zuidgeest","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025120413260120000_15.11.e107737.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.08.001"},{"key":"2025120413260120000_15.11.e107737.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015276","article-title":"Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme","volume":"7","author":"Walters","year":"2017","journal-title":"BMJ Open"},{"key":"2025120413260120000_15.11.e107737.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059230","article-title":"Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997-2020)","volume":"12","author":"Jacques","year":"2022","journal-title":"BMJ Open"},{"key":"2025120413260120000_15.11.e107737.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.1361"},{"key":"2025120413260120000_15.11.e107737.5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2017.05.001","article-title":"Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands","volume":"88","author":"van den Bogert","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2025120413260120000_15.11.e107737.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05818-0","article-title":"Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada","volume":"22","author":"Briel","year":"2021","journal-title":"Trials"},{"key":"2025120413260120000_15.11.e107737.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.07.016"},{"key":"2025120413260120000_15.11.e107737.8","doi-asserted-by":"publisher","DOI":"10.4155\/cli.14.21"},{"key":"2025120413260120000_15.11.e107737.9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7861\/clinmed.2022-0107","article-title":"Public knowledge and information sources for clinical trials among adults in the USA: evidence from a Health Information National Trends Survey in 2020","volume":"22","author":"Yadav","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"2025120413260120000_15.11.e107737.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103520"},{"key":"2025120413260120000_15.11.e107737.11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaoncol.2023.6565","article-title":"Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access","volume":"10","author":"Underhill","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025120413260120000_15.11.e107737.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-020-0302-y","article-title":"Digitizing clinical trials","volume":"3","author":"Inan","year":"2020","journal-title":"NPJ Digit Med"},{"key":"2025120413260120000_15.11.e107737.13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.15003","article-title":"Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders","volume":"88","author":"Coyle","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025120413260120000_15.11.e107737.14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1441"},{"key":"2025120413260120000_15.11.e107737.15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.conctc.2018.06.008","article-title":"Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain","volume":"11","author":"Sommer","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"2025120413260120000_15.11.e107737.16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bmb\/ldad022","article-title":"The future of clinical trials-is it virtual?","volume":"148","author":"Ng","year":"2023","journal-title":"Br Med Bull"},{"key":"2025120413260120000_15.11.e107737.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082485","article-title":"Designing inclusive clinical trials: how researchers can drive change to improve diversity","volume":"388","author":"Anand","year":"2025","journal-title":"BMJ"},{"key":"2025120413260120000_15.11.e107737.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-4197-3","article-title":"Why do patients take part in research? An overview of systematic reviews of psychosocial barriers and facilitators","volume":"21","author":"Sheridan","year":"2020","journal-title":"Trials"},{"key":"2025120413260120000_15.11.e107737.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100829","article-title":"Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews","volume":"23","author":"Rodr\u00edguez-Torres","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2025120413260120000_15.11.e107737.20","article-title":"Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis","volume":"10","author":"Houghton","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120413260120000_15.11.e107737.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01803-6","article-title":"How do study design features and participant characteristics influence willingness to participate in clinical trials? Results from a choice experiment","volume":"22","author":"Thomas","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2025120413260120000_15.11.e107737.22","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70070","article-title":"What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?","volume":"17","author":"Kopanz","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2025120413260120000_15.11.e107737.23","unstructured":"Danish Medicines Agency . The Danish Medicines Agency\u2019s guidance on the implementation of decentralised elements in clinical trials with medicinal products, 2021. Available: https:\/\/laegemiddelstyrelsen.dk\/en\/news\/2021\/guidance-on-the-implementation-of-decentralised-elements-in-clinical-trials-with-medicinal-products-is-now-available\/~\/media\/5A96356760ED408CBFA9F85784543B53.ashx [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.24","unstructured":"Heads of Medicines Agencies, European Commission, European Medicines Agency . Recommendation paper on decentralised elements in clinical trials, 2022. Available: https:\/\/health.ec.europa.eu\/system\/files\/2022-12\/mp_decentralised-elements_clinical-trials_rec_en.pdf [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.25","unstructured":"Clinical Trials Transformation Initiative . Recommendations to Sponsors for Planning Decentralized Trials, 2022. Available: https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2022\/04\/CTTI-Digital-Health-Trials-Planning-Decentralized-Trials-Recs.pdf [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.26","unstructured":"Eurostat . Digital economy and society statistics - households and individuals, 2024. Available: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Digital_economy_and_society_statistics_-_households_and_individuals [Accessed 19 Aug 2025]."},{"key":"2025120413260120000_15.11.e107737.27","unstructured":"Eurostat . Eurostat regional yearbook 2024 edition, 2024. Available: https:\/\/ec.europa.eu\/eurostat\/web\/products-flagship-publications\/w\/ks-ha-24-001 [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.28","unstructured":"Eurostat . Urban-rural Europe - demographic developments in cities, 2024. Available: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Urban-rural_Europe_-_demographic_developments_in_cities [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.29","unstructured":"IQVIA, EFPIA-VE . Assessing the Clinical Trial Ecosystem in Europe \u2013 Final Report, 2024. Available: https:\/\/efpia.eu\/media\/3edpooqp\/assessing-the-clinical-trial-ecosystem-in-europe.pdf [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.30","unstructured":"Orme BK . Getting Started with Conjoint Analysis, Strategies for Product Design and Pricing Research. 2nd edn. Research Publishers LLC, 2010."},{"key":"2025120413260120000_15.11.e107737.31","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0118-z"},{"key":"2025120413260120000_15.11.e107737.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"2025120413260120000_15.11.e107737.33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"2025120413260120000_15.11.e107737.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"2025120413260120000_15.11.e107737.35","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2.4.319"},{"key":"2025120413260120000_15.11.e107737.36","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"2025120413260120000_15.11.e107737.37","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-016-0232-7"},{"key":"2025120413260120000_15.11.e107737.38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2018.01.009","article-title":"Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments","volume":"44","author":"Hazlewood","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2025120413260120000_15.11.e107737.39","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"2025120413260120000_15.11.e107737.40","doi-asserted-by":"crossref","unstructured":"Ryan M , Gerard K , Amaya-Amaya M . Using Discrete Choice Experiments to Value Health and Health Care. Springer, 2008.","DOI":"10.1007\/978-1-4020-5753-3"},{"key":"2025120413260120000_15.11.e107737.41","unstructured":"ChoiceMetrics . Ngene 1.4 User manual and reference guide - the cutting edge in experimental design, 2024. Available: www.choice-metrics.com [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.42","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med"},{"key":"2025120413260120000_15.11.e107737.43","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0520-5"},{"key":"2025120413260120000_15.11.e107737.44","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2011.604383"},{"key":"2025120413260120000_15.11.e107737.45","doi-asserted-by":"crossref","unstructured":"Hensher DA , Rose JM , Greene WH . Mixed Logit Estimation. In: Applied Choice Analysis. Cambridge University Press, 2015:601\u2013705.","DOI":"10.1017\/CBO9781316136232.019"},{"key":"2025120413260120000_15.11.e107737.46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1536867X0700700306","article-title":"Fitting Mixed Logit Models by Using Maximum Simulated Likelihood","volume":"7","author":"Hole","year":"2007","journal-title":"Stata J"},{"key":"2025120413260120000_15.11.e107737.47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jocm.2016.09.005","article-title":"Dummy coding vs effects coding for categorical variables: Clarifications and extensions","volume":"21","author":"Daly","year":"2016","journal-title":"J Choice Model"},{"key":"2025120413260120000_15.11.e107737.48","doi-asserted-by":"publisher","DOI":"10.1002\/hec.984"},{"key":"2025120413260120000_15.11.e107737.49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","article-title":"A Guide to Measuring and Interpreting Attribute Importance","volume":"12","author":"Gonzalez","year":"2019","journal-title":"Patient"},{"key":"2025120413260120000_15.11.e107737.50","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.09.2475"},{"key":"2025120413260120000_15.11.e107737.51","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00006-4"},{"key":"2025120413260120000_15.11.e107737.52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11673-024-10341-3","article-title":"Ethical Considerations in Decentralized Clinical Trials","volume":"20","author":"Bierer","year":"2023","journal-title":"J Bioeth Inq"},{"key":"2025120413260120000_15.11.e107737.53","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602868"},{"key":"2025120413260120000_15.11.e107737.54","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06306-9","article-title":"Hope and meaning-making in phase 1 oncology trials: a systematic review and thematic synthesis of qualitative evidence on patient-participant experiences","volume":"23","author":"Escritt","year":"2022","journal-title":"Trials"},{"key":"2025120413260120000_15.11.e107737.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.023"},{"key":"2025120413260120000_15.11.e107737.56","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpdig.2025.100201","article-title":"Comparison of Participant and Site Perceptions of Decentralized Clinical Trials in the USA","volume":"3","author":"Barge","year":"2025","journal-title":"Mayo Clin Proc Digit Health"},{"key":"2025120413260120000_15.11.e107737.57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s43441-024-00665-y","article-title":"Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: \u201cIt\u2019s About Time we Bring Trials to People\u201d","volume":"58","author":"Richards","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"2025120413260120000_15.11.e107737.58","doi-asserted-by":"crossref","DOI":"10.2196\/29691","article-title":"Patients\u2019 Perspectives on Transforming Clinical Trial Participation: Large Online Vignette-based Survey","volume":"24","author":"Nguyen","year":"2022","journal-title":"J Med Internet Res"},{"key":"2025120413260120000_15.11.e107737.59","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.202200370","article-title":"Opportunities and challenges with decentralized trials in Neuroscience","volume":"65","author":"Burger","year":"2023","journal-title":"Biom J"},{"key":"2025120413260120000_15.11.e107737.60","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15205"},{"key":"2025120413260120000_15.11.e107737.61","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2628"},{"key":"2025120413260120000_15.11.e107737.62","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06521-4","article-title":"A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)","volume":"23","author":"Coyle","year":"2022","journal-title":"Trials"},{"key":"2025120413260120000_15.11.e107737.63","doi-asserted-by":"crossref","DOI":"10.2196\/62947","article-title":"Adaptation of Clinical Research Staff to Decentralized Clinical Trials and Impacts on the Patient-Centered Experience: Qualitative Interview Study","volume":"27","author":"Gamble","year":"2025","journal-title":"J Med Internet Res"},{"key":"2025120413260120000_15.11.e107737.64","doi-asserted-by":"crossref","DOI":"10.2196\/19242","article-title":"Investigator Experiences Using Mobile Technologies in Clinical Research: Qualitative Descriptive Study","volume":"9","author":"McKenna","year":"2021","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025120413260120000_15.11.e107737.65","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100399","article-title":"Patient preferences for using mobile technologies in clinical trials","volume":"15","author":"Perry","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"2025120413260120000_15.11.e107737.66","doi-asserted-by":"crossref","first-page":"1081150","DOI":"10.3389\/fpubh.2022.1081150","article-title":"Decentralized clinical trials (DCTs): A few ethical considerations","volume":"10","author":"Petrini","year":"2022","journal-title":"Front Public Health"},{"key":"2025120413260120000_15.11.e107737.67","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","article-title":"Decentralised clinical trials: ethical opportunities and challenges","volume":"5","author":"Vayena","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2025120413260120000_15.11.e107737.68","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.cct.2020.106219","article-title":"Using digital technologies in clinical trials: Current and future applications","volume":"100","author":"Rosa","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"2025120413260120000_15.11.e107737.69","unstructured":"U.S. Food and Drug Administration . Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, Guidance for Industry, Investigators, and Other Stakeholders, 2023. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations [Accessed 2 Jul 2025]."},{"key":"2025120413260120000_15.11.e107737.70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s43441-025-00751-9","article-title":"Promoting Diversity through an Understanding of Barriers and Drivers for Inclusive Clinical Trials","volume":"59","author":"de Bruin","year":"2025","journal-title":"Ther Innov Regul Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:26:58Z","timestamp":1764883618000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-107737"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107737","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}